Home  Top Stories  Sports  Entertainment  Health News  Business  Personal Finance 
Real Estate  Business Finance  Insurance  Consulting 
Tax News  Forum




Featured Articles







New Cervical Cancer Vaccine More Effective in Younger Girls

December 18th 2005

New Cervical Cancer Vaccine More Effective in Younger Girls

Cancer Prevention

Clinical trials indicated that the new GlazoSmithKline uterine cancer vaccine Cervarix may be twice as effective for younger girls.  The results of the third phase of the trials compared the immune response of girls between the ages of 10 to 14 and girls between the ages of 15 and 24.

The clinical trials were conducted in Europe and Russia by the European drug maker Glaxo.  They involved 158 girls in the lower age group and 458 girls in the older age group.  Each girl received three doses of vaccine over a six month period.

The vaccine offered double the protective power for the younger group.  Forbes reported that Anna-Barbara Moscicki, a pediatrics professor from the University of California said “'Vaccination of pre-teen/adolescent girls against cancer-causing HPV (Human Papillomavirus) before onset of sexual activity will be an important part of the overall strategy for cervical cancer prevention.”


Cervarix could offer a more “durable and efficient protection” if given to younger girls before they become sexually active.  The immune response was twice as effective.  According to Australian website Leading the Charge, the senior researcher at Glaxo said “The concentrations of antibodies to the virus were twice as high in the bloodstreams of the young girls.” 

Antibodies are immune system proteins that seek out and destroy bacteria and viruses.  If a vaccine is introduced into the body with snippets of a specific bacteria or virus the body will learn to deal with and fight off the virus or bacteria. 

Another similar product has been developed by Merck called Gardasil.  Merck’s vaccine is already awaiting approval from US and European regulators.  Like Cervarix, Gardasil will also block two strains of human papillomavirus responsible for 70% of all cervical cancer cases.

The results of phase 3 clinical trials were presented at the annual Conference on Antimicrobial Agents and Chemotherapy under way this weekend in Washington. The trials were also financed by Glaxo.

Comment on this Article at our Forum

Submit your own Article

Cancer Prevention and Treatments

  RSS Feeds to Cancer News

  RSS Feed to our health News

  RSS Feed to all of our News

 Add to My Yahoo!   Subscribe with Pluck RSS reader  

        Subscribe in NewsGator Online 

 Add this feed to Your C-Net 


By Dan Wilson
Best Syndication Staff Writer

Related Books

Keywords & misspellings: cGlaxo Smith Kline Servical Canser Cerverix Gardisil Merk papilomavirus Servarix Serverix cirvical urope prevent    

Web BestSyndication.com

About   Contact   site map

Copyright 2005 Best Syndication                                            Last Updated Saturday, July 10, 2010 09:40 PM